文献速递产科母胎医学生殖医学

胰高血糖素样肽-1受体激动剂围孕期暴露与围产结局

Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes.
PubMed 文献 · BJOG · 2026-10-04

该叙述性综述汇总了GLP-1受体激动剂从孕前到产后的证据,检索PubMed等数据库至2026年。现有观察性数据未显示围孕期意外暴露后不良妊娠结局明显增加,但证据受样本量小、观察性设计、混杂和暴露 ascertainment 不完整限制,不足以排除临床重要风险。

要点

  • 现有观察性数据未发现GLP-1 RA围孕期意外暴露的明确安全信号。
  • 证据有限,不足以排除临床重要风险,需个体化咨询。
  • GLP-1 RA可改善体重代谢,特定人群可能改善生育结局。

核心结论

  • 当前观察性数据未发现GLP-1 RA围孕期意外暴露与明确不良妊娠结局信号相关。
  • 但妊娠安全数据有限,不足以排除临床重要风险,需进一步前瞻性数据和一致报告。

研究设计与样本

  • 叙述性综述,非系统性检索PubMed、Google Scholar、MEDLINE和Embase。
  • 纳入从创刊至2026年发表的英文原创研究、系统综述和荟萃分析。

主要发现

  • GLP-1 RA改善体重和代谢参数,可能改善肥胖和多囊代谢性卵巢综合征(PMOS)女性的生育结局。
  • 现有观察性数据未显示围孕期暴露后不良妊娠结局(先天畸形、妊娠期高血压疾病、妊娠期糖尿病、早产、胎儿生长、死产)明显增加。

临床怎么用

  • 对围孕期意外暴露的女性应基于现有证据进行个体化咨询,不应假定暴露已确定有害或已证明安全。
  • 需加强常规询问和一致报告妊娠期GLP-1 RA暴露。

局限性

  • 证据受样本量小、观察性研究设计、潜在混杂和暴露与结局 ascertainment 不完整限制。
  • 缺乏稳健的妊娠安全性数据,不足以排除临床重要风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An increasing number of women of childbearing age worldwide are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and are advised to use effective contraception during treatment. Nevertheless, maternity services are encountering increasing numbers of women exposed to GLP-1 RAs shortly before conception or during pregnancy. The true extent of exposure is likely underestimated because routine enquiry is not universal. The effects of GLP-1 RA exposure on pregnancy remain poorly understood, and there is currently limited guidance on counselling women with inadvertent periconceptional exposure. DESIGN: Narrative review. POPULATION OR SAMPLE: Original research articles, systematic reviews and meta-analyses published in English from inception to 2026 were considered for inclusion. METHODS: A non-systematic literature search of PubMed, Google Scholar, MEDLINE and Embase was undertaken. Evidence relating to GLP-1 RA use from preconception through pregnancy and the postnatal period was reviewed. MAIN OUTCOME MEASURES: Key findings relating to preclinical safety data, human pregnancy outcomes-including congenital anomalies, hypertensive disorders of pregnancy, gestational diabetes, preterm birth, fetal growth and stillbirth; pharmacokinetic and drug washout considerations. RESULTS: GLP-1 RAs improve weight and metabolic parameters and may improve fertility outcomes in selected populations, including women with obesity and polycystic metabolic ovarian syndrome (PMOS). Available human observational data have not demonstrated a clear increase in adverse pregnancy outcomes following periconceptional exposure. However, the evidence base is limited by small numbers, observational study designs, potential confounding and incomplete ascertainment of exposure and outcomes. CONCLUSIONS: Current observational data have not identified a clear safety signal associated with inadvertent periconceptional exposure to GLP-1 RAs. However, robust pregnancy safety data remain limited and are insufficient to exclude clinically important risks. Further prospective data and consistent reporting of pregnancy exposures are needed. In the meantime, women with inadvertent exposure should receive individualised counselling based on the available evidence rather than assuming that exposure is either established to be harmful or proven to be safe.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lau KGY, Chopra A, Mullins E, et al. Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy: Periconception Exposure and Perinatal Outcomes. BJOG. 2026. PMID: 42830218. doi:10.1111/1471-0528.70339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。